{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T02:17:56Z","timestamp":1767147476122,"version":"build-2238731810"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,11]],"date-time":"2021-07-11T00:00:00Z","timestamp":1625961600000},"content-version":"vor","delay-in-days":191,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2016YFE0202800"],"award-info":[{"award-number":["2016YFE0202800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.lrr.2021.100258","type":"journal-article","created":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T12:52:03Z","timestamp":1626267123000},"page":"100258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Oral etoposide combined with oral arsenic plus retinoic acid for two cases with newly diagnosed high-risk acute promyelocytic leukemia during COVID19 pandemic"],"prefix":"10.1016","volume":"16","author":[{"given":"Sheng-ye","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-hong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Prof.","given":"Hao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.lrr.2021.100258_bib0001","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of aml in adults: 2017 eln recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.lrr.2021.100258_bib0002","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1182\/blood-2009-07-233387","article-title":"Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the european apl group experience","volume":"115","author":"Ades","year":"2010","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.lrr.2021.100258_bib0003","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","article-title":"Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (aml17): results of a randomised, controlled, phase 3 trial","volume":"16","author":"Burnett","year":"2015","journal-title":"Lancet. Oncol."},{"issue":"2","key":"10.1016\/j.lrr.2021.100258_bib0004","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.lrr.2021.100258_bib0005","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the european leukemianet","volume":"133","author":"Sanz","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.lrr.2021.100258_bib0006","doi-asserted-by":"crossref","first-page":"721","DOI":"10.6004\/jnccn.2019.0028","article-title":"Acute myeloid leukemia, version 3.2019, nccn clinical practice guidelines in oncology","volume":"17","author":"Tallman","year":"2019","journal-title":"J. Nat. Comprehen. Canc. Netw.: JNCCN."},{"issue":"5","key":"10.1016\/j.lrr.2021.100258_bib0007","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/bjh.13809","article-title":"Long-term survival of acute promyelocytic leukaemia patients treated with arsenic and retinoic acid","volume":"174","author":"Zhu","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"25","key":"10.1016\/j.lrr.2021.100258_bib0008","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1182\/blood-2010-01-266007","article-title":"Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome","volume":"115","author":"Sanz","year":"2010","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.lrr.2021.100258_bib0009","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2016.71.6183","article-title":"Arsenic Trioxide consolidation allows anthracycline dose reduction for pediatric patients with acute promyelocytic leukemia: report from the children\u2019s oncology group phase iii historically controlled trial aaml0631","volume":"35","author":"Kutny","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.lrr.2021.100258_bib0010","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.2019000760","article-title":"The simpler, the better: oral arsenic for acute promyelocytic leukemia","volume":"134","author":"Zhu","year":"2019","journal-title":"Blood"},{"issue":"33","key":"10.1016\/j.lrr.2021.100258_bib0011","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1200\/JCO.2013.48.8312","article-title":"Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial","volume":"31","author":"Zhu","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lrr.2021.100258_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106353","article-title":"Acute leukemia in the time of covid-19","volume":"92","author":"Gavillet","year":"2020","journal-title":"Leuk.. Res."},{"issue":"17","key":"10.1016\/j.lrr.2021.100258_bib0013","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1002\/cncr.32180","article-title":"Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: a 5-year prospective study","volume":"125","author":"Gill","year":"2019","journal-title":"Canc."},{"issue":"7","key":"10.1016\/j.lrr.2021.100258_bib0014","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S1470-2045(18)30295-X","article-title":"Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet. Oncol."},{"issue":"Suppl 2","key":"10.1016\/j.lrr.2021.100258_bib0015","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/S0049-3848(14)50019-9","article-title":"Thrombo-hemorrhagic deaths in acute promyelocytic leukemia","volume":"133","author":"Breccia","year":"2014","journal-title":"Thromb. Res."}],"updated-by":[{"DOI":"10.1016\/j.lrr.2022.100307","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000}}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221304892100025X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221304892100025X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:08:24Z","timestamp":1761959304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221304892100025X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":15,"alternative-id":["S221304892100025X"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2021.100258","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral etoposide combined with oral arsenic plus retinoic acid for two cases with newly diagnosed high-risk acute promyelocytic leukemia during COVID19 pandemic","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2021.100258","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100258"}}